TY - JOUR
T1 - Update on Edoxaban for the prevention and treatment of thromboembolism
T2 - Clinical applications based on current evidence
AU - Zalpour, Ali
AU - Oo, Thein Hlaing
N1 - Publisher Copyright:
© 2015 Ali Zalpour and Thein Hlaing Oo.
PY - 2015
Y1 - 2015
N2 - Vitamin K antagonists (VKA) and heparins have been utilized for the prevention and treatment of thromboembolism (arterial and venous) for decades. Targeting and inhibiting specific coagulation factors have led to new discoveries in the pharmacotherapy of thromboembolism management. These targeted anticoagulants are known as direct oral anticoagulants (DOACs). Two pharmacologically distinct classes of targeted agents are dabigatran etexilate (Direct Thrombin Inhibitor (DTI)) and rivaroxaban, apixaban, and edoxaban (direct oral factor Xa inhibitors (OFXaIs)). Emerging evidence from the clinical trials has shown that DOACs are noninferior to VKA or low-molecular-weight heparins in the prevention and treatment of thromboembolism. This review examines the role of edoxaban, a recently approved OFXaI, in the prevention and treatment of thromboembolism based on the available published literature. The management of edoxaban in the perioperative setting, reversibility in bleeding cases, its role in cancer patients, the relevance of drug-drug interactions, patient satisfaction, financial impacts, and patient education will be discussed.
AB - Vitamin K antagonists (VKA) and heparins have been utilized for the prevention and treatment of thromboembolism (arterial and venous) for decades. Targeting and inhibiting specific coagulation factors have led to new discoveries in the pharmacotherapy of thromboembolism management. These targeted anticoagulants are known as direct oral anticoagulants (DOACs). Two pharmacologically distinct classes of targeted agents are dabigatran etexilate (Direct Thrombin Inhibitor (DTI)) and rivaroxaban, apixaban, and edoxaban (direct oral factor Xa inhibitors (OFXaIs)). Emerging evidence from the clinical trials has shown that DOACs are noninferior to VKA or low-molecular-weight heparins in the prevention and treatment of thromboembolism. This review examines the role of edoxaban, a recently approved OFXaI, in the prevention and treatment of thromboembolism based on the available published literature. The management of edoxaban in the perioperative setting, reversibility in bleeding cases, its role in cancer patients, the relevance of drug-drug interactions, patient satisfaction, financial impacts, and patient education will be discussed.
UR - http://www.scopus.com/inward/record.url?scp=84940764141&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940764141&partnerID=8YFLogxK
U2 - 10.1155/2015/920361
DO - 10.1155/2015/920361
M3 - Review article
C2 - 26351456
AN - SCOPUS:84940764141
SN - 1687-9104
VL - 2015
JO - Advances in Hematology
JF - Advances in Hematology
M1 - 920361
ER -